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Aim: To fabricate PEGylated liposomes which preserve the activity of hydrophobic 
Wnt3A protein, and to demonstrate their efficacy in promoting expansion of 
osteoprogenitors from human bone marrow. Methods: PEGylated liposomes 
composed of several synthetic lipids were tested for their ability to preserve Wnt3A 
activity in reporter and differentiation assays. Single-molecule microspectroscopy 
was used to test for direct association of protein with liposomes. Results: Labeled 
Wnt3A protein directly associated with all tested liposome preparations. However, 
Wnt3A activity was preserved or enhanced in PEGylated 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC) liposomes but not in PEGylated 1,2-dimyristoyl-sn-glycero-
3-phosphocholine (DMPC) liposomes. PEGylated Wnt3A liposomes associated with 
skeletal stem cell populations in human bone marrow and promoted osteogenesis. 
Conclusion: Active Wnt protein-containing PEGylated liposomes may have utility for 
systemic administration for bone repair.
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Published online: 29 March 2017
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Liposomes are artificial vesicles, ranging in 
size from approximately 25 nm to 2.5 μm, 
which may be composed of a variety of syn-
thetic or naturally derived phospholipids [1]. 
They have found wide use in both basic sci-
ence and in the pharmaceutical industry, 
and more than 15 liposome-based drugs 
currently have clinical approval for a range 
of medical applications, including infection 
control [2], vaccine delivery [3] or anticancer 
medications [4]. Many more are in current 
clinical trials [5]. They are beneficial for drug 
delivery when they are able to offer superior 
therapeutic efficacy and/or safety over exist-
ing formulations. This is based on several 
important advantages, including improved 
solubility, protection of an entrapped drug 
from degradation, increased cellular uptake 
and improvements in a drug’s pharmacoki-
netic and tissue distribution profile. A major 
step forward for clinical applications came 
with the advent of ‘stealth’ liposomes, which 
display PEG on their surfaces (‘PEGylated’ 
liposomes) [6]. PEGylated liposomes exhibit 
prolonged circulation times as they are better 
able to evade uptake and removal by the retic-
ular endothelial system. Long-circulating 
nano-sized (∼100 nm diameter) PEGylated 
liposomes preferentially accumulate and 
concentrate drugs within solid tumors due 
to the ‘enhanced permeability and retention’ 
effect which, while not entirely understood, 
is thought to be a result from an immature 
and leaky vasculature within the tumor [7,8].
While the primary success of circulating 
liposomal therapies has been in the field of 
cancer sciences, evidence is emerging that 
liposomes may be attractive drug delivery 
vehicles for other indications, including 
regenerative medicine [9]. Liposomes can 
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carry a wide range of cargoes, including small mol-
ecules, nucleic acids, proteins and peptides, and there-
fore may act as systemic or local delivery systems for 
therapeutic agents that might otherwise be ineffective 
due to poor bioavailability or due to degradation. For 
example, liposomes have been used to deliver a vari-
ety of molecules when tethered to biomaterial scaffolds 
in order to promote regeneration [10], or have been 
used systemically to entrap and deliver poorly soluble 
molecules such as dexamethasone [11], or highly solu-
ble molecules such as bisphosphonates [12,13]. Added 
functionality may be achieved by including surface 
modification to target liposomes to a desired tissue. 
For example, liposomes have been modified with 
surface groups including (AspSerSer)
6
 or bisphospho-
nate [14,15], type II collagen antibody [16] or E-selectin 
aptamer [17] for targeting to bone, cartilage and bone 
marrow, respectively.
We are investigating the notion that liposomes can 
be used for the systemic delivery of Wnt proteins. Wnt 
proteins are a family of secreted glycoprotein growth 
factors which, on binding to cell surface receptors 
Frizzled and Lrp5/6, activate the intracellular Wnt sig-
naling pathway. Activation of Wnt signaling may have 
a diverse range of effects and is highly dependent on 
the target cell or tissue, but is particularly important 
in bone homeostasis and disease [18,19]. Several human-
ized monoclonal antibodies which bind to and inacti-
vate inhibitors of Wnt signaling, such as DKK1 [20] or 
SOST [21] are currently in clinical trials, with recent 
data suggesting efficacy in promoting bone forma-
tion in osteoporotic patients [22,23]. The efficacy of 
these monoclonal antibodies in fracture healing is less 
clear, however, which may be related to their prolonged 
in vivo activity (with half-lives of > 4 weeks [24]), and 
the fact that it is known that elevated Wnt signaling 
can have both positive and negative effects depending 
on the timing of delivery [25]. In these cases, delivery 
of short-acting molecules such as Wnt proteins rather 
than antibodies will provide much better control of 
temporal activation of signaling, as well as the poten-
tial of selective localization of the molecule to the 
injury site.
As Wnt proteins carry fatty acid modifications 
which render them unstable in aqueous solution [26,27], 
liposome incorporation (for one member of the Wnt 
family, Wnt3A) has been shown to be an effective 
method of preserving both in vitro and in vivo stabil-
ity and activity [28–32]. However, several challenges and 
unanswered questions remain. Inclusion of PEGylated 
lipids has been shown to abolish the activity of current 
liposome preparations [30], restricting their use to local 
application or injection [29,32]. Local injection may dis-
turb the hematoma or fracture callus (the integrity of 
which is important in healing) and in many cases may 
be difficult (requiring radiological expertise), painful 
and increase the risk of infection, therefore in many 
cases systemic delivery may be advantageous. It also 
remains unclear whether PEGylation prevents lipo-
somal interaction with Wnt3A protein or inhibits 
 subsequent cell interaction.
In this study, we focused on optimizing an 
active Wnt3A liposomal formulation incorporating 
PEGylation that could subsequently be used for sys-
temic delivery. We tested the hypothesis that Wnt3A 
can stably associate with neutrally charged 100 nm 
‘stealth’ liposomes, remain active in these particles 
and can be efficiently delivered to skeletal stem cells. 
We also provide, for the first time, evidence of a direct 
interaction of Wnt proteins with liposomal carriers by 
using single-molecule microspectroscopy techniques. 
Finally, we determined the optimal liposome com-
position and measured its relative uptake by differ-
ent cell populations found in bone marrow isolates in 
vitro. Our results demonstrate that incorporation into 
PEGylated DOPC liposomes enhanced Wnt3A pro-
tein activity and that these liposomes can be used as 
delivery vesicles of Wnt3A to stromal/skeletal stem cell 
populations of the bone marrow. A schematic overview 
of our approach is presented in Figure 1.
Materials & methods
For full methods, please refer to the supplementary 
 information.
Bone marrow cells
Bone marrow mononuclear cells (BMMNCs) were 
isolated from femoral samples obtained from hemato-
logically normal individuals undergoing hip replace-
ment surgery at Southampton General Hospital or 
Spire Hospital Southampton, with the approval of the 
appropriate Local Research Ethics Committee (LREC 
194/99/1), as previously described [33]. Cells were 
maintained in basal medium (α-MEM containing 
10% FBS and 100 μg/ml penicillin/streptomycin) or 
osteogenic medium (basal medium supplemented with 
100 μM ascorbate-2-phosphate, 10 nM dexametha-
sone and 5 mM β-glycerophosphate), with the excep-
tion of when exposed to Wnt3A protein (5036-WN, 
R&D Systems, McKinley, MN, USA) or liposomes, 
where serum concentration in the media was 5%.
Liposome preparation
A total of 14 μ moles of lipids (Avanti Polar Lipids, AL, 
USA) were dissolved in 1 ml chloroform/methanol (3:1 
v/v) in a 10-ml round-bottomed flask, and dried to a 
thin film under a nitrogen gas stream for 5 min, with 
further vacuum desiccation overnight at room tem-
www.futuremedicine.com 847
Figure 1. A schematic overview of the experimental approach of the study.
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perature. Liposome PEGylation was achieved by adding 
5 molar% 1,2-distearoyl-sn-glycero-3-phosphoethanol-
amine-N-[amino(polyethylene glycol)] (DSPE-PEG) 
lipid to either DMPC or DOPC lipids. The thin lipid 
layer was then hydrated with 1 ml phosphate-buffered 
saline (PBS), and placed in a water bath for 1 h at 37°C 
with vortexing every 10 min. Extrusion was carried out 
on a heating block (Avanti) at 37°C, 41-times through 
a 100 nm polycarbonate membrane (GE Healthcare/
Whatman, Little Chalfont, UK). In order to minimize 
the contamination of the liposome samples with free 
lipids, the solutions were ultracentrifuged (Beckman 
Coulter, CA, USA) at 100,000 × g for 60 min at 4°C. 
The liposome pellet was then resuspended in 1 ml PBS 
and liposomes were subsequently stored at 4°C. Loading 
of Wnt3A was carried out either during lipid film hydra-
tion, with 2 μg/ml of Wnt3A in PBS or after liposome 
formation, by incubation with 2 μg/ml Wnt3A at room 
temperature, for up to 24 h, followed by ultracentrifu-
gation and resuspension in PBS at the initial volume. 
848 Nanomedicine (Lond.) (2017) 12(8)
Figure 2. DMPC and DOPC PEGylated liposomes are stable, unilamellar nanoparticles of approximately 100 nm in 
size and low polydispersity. PEGylation degree quantified by GC reached approximately 5 mol% as expected for 
both DMPC (A) and DOPC (B) liposomes. TEM micrographs of fixed and negatively stained liposome preparations 
(C), at 20,000x magnification showing uniform and unilamellar appearance of liposomes, and at 80,000× 
magnification showing uneven structures attributable to PEGylation and fluidity changes of the liposomal bilayer. 
Nanoparticle tracking analysis showed a narrow size distribution (∼100 nm) of liposomal preparations (D) and 
provided information on nanoparticle concentration (1014 particles/ml). Size measurements by dynamic light 
scattering (E; n = 3) confirmed size stability of the preparations for up to 21 days. 
DMPC: 1,2-dimyristoyl-sn-glycero-3-phosphocholine; DOPC: 1,2-dioleoyl-sn-glycero-3-phosphocholine;  
GC: Gas chromatography.
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For preparation of fluorescent liposomes, 100 μM of 
a lipophilic dye: DiO or DiI (Life Technologies, CA, 
USA) was mixed with the lipids before nitrogen drying. 
Where indicated, fluorescent liposomes were produced 
by incorporating a biotinylated lipid (DSPE-PEG Bio-
tin, 2 molar%; Avanti) into the lipid mixture and after 
formation incubated with streptavidin-AF647 conjugate 
(BioLegend, CA, USA) at a 1:1 biotin to  streptavidin 
molar ratio for 20 min at room temperature.
Liposomal Wnt activity assay
The luciferase assay was performed on a 3T3 mouse 
embryonic fibroblast cell line (Enzo Life Sciences, 
NY, USA), modified to expresses the firefly luciferase 
reporter gene under the control of Wnt-responsive pro-
moters TCF/LEF. Cells (3 × 104 cells/well, in 50 μl 
assay media; 96-well plate) were treated with 100 ng/
ml Wnt3A protein or 5 μl liposomal Wnt3A in 50 μl 
of DMEM. Plates were incubated at 37°C for 18 h, fol-
lowed by addition of 100 μl/well of luciferase substrate 
diluted in luciferase buffer (Steady-Glo, Promega, WI, 
USA). After 10 min of reaction and cell lysis, the che-
miluminescence signal was read (0.1 s/well) on a Vari-
oscan Flash microplate reader (Thermo Fisher Scien-
tific, MA, USA). To control for cell count, cell lysates 
were analyzed with the use of Quant-iT™ PicoGreen® 
dsDNA Reagent (Thermo Fisher Scientific) according 
to manufacturer’s protocol. Fluorescence was measured 
on an FLx800 fluorescence microplate reader (Biotek, 
VT, USA) with the excitation/emission wavelength set 
to 480/520 nm, respectively.
Protein quantification within the liposomal 
bilayer
Quantification of Wnt3A protein in liposomal prepa-
rations was carried out using a fluorescent CBQCA 
Protein Quantitation Kit (Molecular Probes, OR, 
USA), according to the manufacturer’s protocol.
Single-molecule spectroscopy
DiO-labeled liposomes and an Atto680-maleimide-
labeled (Sigma, MO, USA) ‘carrier-free’ version of 
the Wnt3A protein (5036-WN/CF, R&D Systems) 
as well as BSA (as negative control), or Alexa Fluor 
647 (AF647)-streptavidin (Thermo Fisher Scientific; 
as positive control) were used for the single-molecule 
experiments. For TIRFM measurements, borosilicxate 
glass coverslips (VWR, PA, USA) were cleaned using 
an argon plasma cleaner (PDC-002, Harrick Plasma, 
NY, USA) for 1 h to remove any fluorescent residues 
and coated with 0.01% poly-L-lysine solution (Sigma). 
Next, 100 μl of 100× diluted liposome sample was 
placed on each slide immediately prior to imaging, and 
1 μl of 4000 × diluted 1 μM protein was added to the 
slide. As a negative control, 0.1% of Triton-X in PBS was 
added to destroy the liposomes. TIRFM experiments 
were performed on a bespoke instrument [34] and were 
used to generate spatially resolved images (Figure 4E), 
this imaging technique axially restricts the detectable 
fluorescence signal to within approximately 200 nm 
from the sample glass/water interface of the coverslip. 
For each dataset, 3 × 3 image grids were measured in 
three different automated regions (Optiscan III, Prior, 
UK) to prevent user bias. Images were recorded at 33 
frames per second for 100 frames, first from the red 
channel (Atto680 and AF647 emission) with 641 nm 
illumination, followed by 100 frames in the green chan-
nel (DiO emission) with 488 nm illumination. Single-
molecule confocal measurements were performed on 
a custom-built instrument described previously [35,36]. 
The experiments were performed in two color coinci-
dence detection (TCCD) mode, in which light from 
488 to 633 nm lasers were combined and focused to a 
diffraction limited spot, through which labeled mol-
ecules are able to diffuse, be excited and detected. For 
all confocal measurements, the samples were diluted 
to concentrations of approximately 100 pM, and the 
data were collected for 400 s (photons counted in time-
bins of 50 μs). As a negative control, 0.025% solution 
of 3-[(3-cholamidopropyl)dimethylammonio]-1-pro-
panesulfonate (CHAPS) was added to destroy the 
liposomes. Data analysis was performed using custom-
written procedures in Igor Pro (Wavemetrics, OR, 
USA). The co-ordinates of each detected spot in the 
green channel are analyzed in the red channel (after 
the frames are averaged over the whole stack and the 
background subtracted), and if there was a pixel above 
the applied red threshold value (mean intensity + 5 SD) 
then a positive coincidence is recorded. The number 
of chance coincident events was estimated by perform-
ing the previously described analyzes on green and red 
image stacks from different field-of-views. The asso-
ciation quotient (Q) for both methods was calculated 
according to the following equation:
Q
A E
C E= -
-
Where:
Q – association quotient;
C – number of coincident events in both red and green 
channels;
E – estimated rate at which coincident events occur by 
chance;
A – events rate in the green channel.
Flow cytometry & image stream
Uptake of DiI-labeled liposomes by adherent bone mar-
row stromal cells (BMSCs) at P1 was studied by flow 
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Figure 3. Wnt3A is active in PEGylated DOPC liposomes when associated passively post-extrusion. Addition of 
Wnt3A protein to lipid suspensions prior to extrusion resulted in loss of activity of all preparations except for 
DMPC (A), while incubation after formation (for 24 h) resulted in liposome preparations with similar activities 
to native protein, except for DMPC + PEG (B). After Wnt3A liposome formation by incubation and subsequent 
ultracentrifugation, the majority of the protein remains in the liposomal pellet regardless of activity, as quantified 
by western blotting (C). This suggests that loss of activity in (A) is not due to loss of protein, but rather loss 
of protein activity. Efficiency of incorporation was calculated based on the Wnt3A mass associated with the 
liposomal pellet out of total detectable by assay and was: 90 and 79% for DMPC/PEG and DOPC/PEG, respectively. 
Incubation for 24 h was sufficient to partition the majority of the Wnt3A protein into the liposome fraction (D), as 
confirmed by WB analysis of the liposomal pellets and supernatants. Data presented as mean ± SD, n = 3 separate 
experiments.  
*p < 0.05, **p < 0.01 for liposome preparations versus Wnt3A reference. Statistical significance assessed by ANOVA 
with Tukey’s correction.  
DMPC: 1,2-dimyristoyl-sn-glycero-3-phosphocholine; DOPC: 1,2-dioleoyl-sn-glycero-3-phosphocholine.
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cytometry. Cells were seeded into 6-well plates at 4 × 
104 cells/well, allowed to adhere overnight and serum 
starved (α-MEM supplemented with 0.5 % FBS and 
100 U/ml penicillin and 100 μg/ml streptomycin per 
well) for 24 h. Next, approximately 107 liposomes/cell 
were added per well. After 1, 3, 6 and 24 h cells were 
trypsinized and assayed by flow cytometry on a Guava 
Easycyte Mini Flow Cytometer (Merck Millipore, 
MA, USA). Uptake of DiO-labeled or AF647-labeled 
liposomes was studied on fresh bone marrow isolates 
after 3 h of incubation in suspension with approxi-
mately 106 liposomes/cell. Following this, immunos-
taining for CD14, STRO-1 and Glycophorin A (GPA) 
was carried out as described previously [25]. Cells were 
assayed on an FACS Canto II cytometer (BD Biosci-
ences, NJ, USA) or Image Stream (Amnis, WA, USA). 
All flow cytometry experiments were analyzed using 
FlowJo v10 software. Data were acquired and analyzed 
as described previously [25].
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism 6 software (GraphPad, CA, USA). Liposomal 
Wnt activity, uptake of liposomes and cell viability 
were analyzed using ANOVA with Tukey’s post hoc 
correction. Curve fitting for liposome uptake was con-
ducted using a hyperbola equation model. Data are 
presented as means ± SD and the significance level was 
set at p < 0.05.
Results
PEGylated liposomes can be fabricated with 
uniform physical properties, & are stable for 
prolonged time periods
We first fabricated liposomes by rehydration of lipids 
followed by extrusion through polycarbonate porous 
membranes. To make ‘stealth’ liposomes, which dis-
play PEG groups on their surface, we incorporated 
5% molar mass of DSPE-PEG prior to rehydration of 
DMPC or DOPC liposomes.
To confirm PEGylation, we measured liposome 
composition using gas chromatography (Figure 2A & B). 
We found that DSPE-PEG was successfully incorpo-
rated in liposomes with the predicted efficiency (4.8 
mol% for DMPC and 4.6 mol% for DOPC lipo-
somes). Gas chromatograms of homogenous DMPC 
or DOPC liposomes did not show any peak for DSPE, 
as expected (Supplementary Figure 1A & B).
We next analyzed size distribution, unilamellarity 
and stability of PEGylated liposomes. TEM imaging of 
dispersed PEGylated DMPC liposomes revealed uni-
form size distribution and no evidence of multilamellar-
ity (Figure 2C). We also observed uneven structures with 
higher electron-absorbing properties in the liposomes, 
likely attributable to PEGylation due to fluidity changes 
of the liposomal bilayer (Figure 2C, inset). Nanoparticle 
tracking analysis, an imaging technique which mea-
sures the Brownian movement of nanoparticles by their 
light scattering properties, revealed a narrow size distri-
bution of liposome preparations (∼100 nm), low poly-
dispersity index and final nanoparticle concentrations 
of approximately 1014 particles/ml (Figure 2D & Table 1). 
Liposomes were stable in size for up to 21 days, with 
no change in the hydrodynamic radius as measured by 
dynamic light  scattering (Figure 2E).
Wnt3A protein is active in ‘stealth’ liposomal 
preparations
Next, we tested the hypothesis that PEGylated lipo-
somes can support the activity of incorporated Wnt 
protein, a necessary property for the use of liposomes as 
circulating Wnt carriers. A previous report [30] showed 
that inclusion of DSPE-PEG in otherwise active Wnt-
containing liposome preparations abrogated the activ-
Table 1. Size and concentration of liposome preparations.
Preparation DMPC/DSPE-PEG DOPC/DSPE-PEG
Mean (size) 98.7 nm 102 nm
Mode (size) 91.3 nm 109.8 nm
SD (size) 25.4 nm 23.1 nm
d10 68.0 nm 71.0 nm
d50 90.9 nm 96.4 nm
d90 117.9 nm 118.8 nm
Concentration (particles/ml) 1.44 × 1014 1.66 × 1014 
PI 0.084 0.051
Summary of size, concentration and polydispersity index (PI) of the liposome preparations. d10, d50, d90 -% levels below which the sample 
population falls, giving an indication of the overall spread of size, in other words, 50% of DMPC/PEG liposomes are ≤90.9 nm.
DMPC: 1,2-dimyristoyl-sn-glycero-3-phosphocholine; DOPC: 1,2-dioleoyl-sn-glycero-3-phosphocholine; DSPE: 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine.
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Figure 4. Wnt association with liposomes measured at the single-molecule level (see facig page). Wnt3A association with liposomes 
was confirmed by two single-molecule spectroscopy techniques, single-molecule confocal microscopy TIRFM, shown schematically 
in (A & D), respectively. Using these techniques, association of labeled Wnt3A or control protein (BSA) with DiO-labeled liposomes 
was determined using the Q-value (see ‘Materials & methods’ section). TCCD showed that even when working with picomolar 
concentrations of both liposomes and proteins in a microfluidic setup, the association of Wnt3A (C) with liposomes is 10× higher 
than that for BSA with liposomes (B; Q = 2.20 vs 0.20%, red lines on histograms). The gray lines show events that are due to multiple 
nonassociated molecules giving rise to coincidence due to their chance simultaneous occupation of the confocal volume (see 
‘Materials & methods’ section). Images recorded on TIRFM showed 31.15% level of coincidence for Wnt3A protein (F) versus 6.89% for 
BSA (E), even when the control protein was tested at a higher concentration. Scale bars = 5 μm. 
TCCD: Two-colour coincidence detection; TIRFM: Total internal reflection fluorescence microscopy.
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ity of the protein. We considered that Wnt3A-liposome 
activity could be preserved by careful optimization of 
liposome composition and preparation. We examined 
two types of preparations, one where the protein was 
added prior to lipid extrusion, or another by  incubation 
with formed liposomes post extrusion.
When Wnt3A was added prior to extrusion, the 
resultant DMPC liposomes had activities that were not 
significantly different from protein alone (p = 0.36; 
Figure 3A), assuming complete incorporation of protein 
with the liposomes. This may represent an underesti-
mation of activity, as it is likely that some protein was 
lost to supernatant or precipitation and therefore (as 
previously reported) it is possible that DMPC liposome 
incorporation augments Wnt3A activity. PEGylation 
had a negative effect on liposome activity, resulting in a 
decrease in activity of DMPC liposomes (58 ± 6.3% of 
in the initial DMPC activity, p < 0.05). DOPC-Wnt3A 
liposomes were less active than Wnt3A (27 ± 9% of 
Wnt3A reference activity, p < 0.01), but PEGylation 
had no effect on their activity.
In contrast, when Wnt3A was incorporated into 
liposomes after their formation, by incubation of the 
protein for 24 h in the presence of the liposomes, the 
activity of Wnt3A-DOPC liposomes was unchanged 
or increased compared with Wnt3A (Figure 3B). More-
over, PEGylation had no effect on the activity of 
DOPC liposomes (p = 0.65). In agreement with previ-
ous studies [28], we found that 24 h of incubation of 
Wnt3A with either PEGylated or unPEGylated lipo-
somes was sufficient to partition the majority of the 
Wnt3A protein into the liposome fraction. >80% of 
protein was found in the pellet fraction of ultracentri-
fuged liposome suspension at this time point, measured 
by a protein quantification assay and western blotting 
(Figure 3C & D). Wnt3A incorporation efficiency var-
ied between liposomal preparations (90 and 79% for 
DMPC/PEG and DOPC/PEG, respectively). This 
process of association of protein with liposomes was 
time-dependent, with an increasing mass of Wnt3A 
protein found in the pellet with longer incubation 
times (Supplementary Figure 2). The size and distribu-
tion of Wnt3A-associated DOPC liposomes was not 
significantly different from that of control liposomes 
(mean 112 nm ± 27 nm SD, n = 3).
Together these data demonstrate that PEGylated 
liposome preparations are suitable for maintaining the 
activity of Wnt3A and therefore can be used as delivery 
vesicles for this protein.
Wnt3A association with liposomes can be 
visualized at the single-molecule level
While the biochemical methods described above are 
useful for determining the association of a protein 
with a given fraction of a particulate suspension, they 
do not directly reveal spatial interactions of proteins 
with liposome carrier. To prove such interactions, we 
next employed single-molecule microscopic methods, 
two-colour coincidence detection (TCCD) and total 
internal reflection fluorescence microscopy (TIRFM). 
For visualization, liposomes were labeled with the lipo-
philic fluorescent dye, DiO and Wnt3A protein was 
labeled with an Atto680-maleimide, which reacts with 
sulphydryl groups on proteins. As a positive control, 
biotinylated liposomes incubated with AF647-labeled 
streptavidin were prepared. Atto680-labeled BSA was 
used as negative control, as BSA is not predicted to 
interact with membranes.
In single-molecule confocal TCCD measurements, 
488 and 633 nm radiation are combined and focused 
to a diffraction-limited volume [36,37] (see Figure 4A for 
cartoon schematic). As molecules transit this probe vol-
ume, they may give rise to a green burst of fluorescence 
if tagged with a 488 nm excitable dye, and a red burst 
if tagged with a 633 nm excitable dye. If both types 
of dye are present, there will be a simultaneous ‘coin-
cident’ burst in both channels. Measurements were 
first performed on a dual-labeled (AF488 and AF647) 
DNA duplex (Supplementary Figure 3A), to establish a 
value for the maximum measurable co-incidence; this is 
usually less than 30% due to imperfect overlap of the 
two wavelengths [38]. This was found to be 15.70%. In 
contrast, the negative control (liposomes incorporating 
BSA-Atto680) was found to have a co-incidence value of 
0.22 ± 0.10%, n = 3 (Figure 4B). Biotin-tagged liposomes 
labeled with AF647-tagged streptavidin were found next 
to have a coincidence value of 9.20% (Supplementary Fig-
ure 3B). Finally, Wnt3A-Atto680-tagged DiO liposomes 
were found to have co-incidence values of 2.51 ± 0.35%, 
n = 3 (Figure 4C). BSA and Wnt3A-Atto680-tagged 
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PEGylated DiO liposomes had comparable values of co-
incidence to the unPEGylated samples (values of 0.27 
and 2.84%, respectively; Supplementary Figure 3C).
Second, TIRFM was used to measure the colocal-
ization of fluorescent tags. TIRFM is a technique that 
allows for the high-sensitivity detection of fluorophore-
www.futuremedicine.com 855
Figure 5. PEGylated DOPC liposomes are taken up by monocytes and skeletal progenitor cells within mixed populations of human 
bone marrow. (A) Liposomes were labeled by two different strategies (passive incorporation of DiO or covalent attachment of AF647) 
and human bone marrow populations were subsequently examined for liposome uptake/association by flow cytometry. Overall 
cell association was greater for AF647-tagged liposomes than for DiO (left panels, A) but in both cases predominant association 
was in cells in the ‘monocyte’ gate based on light scattering properties (right panels, [A]). (B) Quantification of DiO+ or AF647+ cells 
within the cell populations gated for monocyte, granulocyte and lymphocyte demonstrated very low uptake in granulocyte- and 
lymphocyte-gated cells compared with monocyte-gated cells. Further analysis of populations within the monocyte scatter gate 
by staining for CD14, STRO-1 and GPA antibodies revealed a higher uptake in CD14+ monocytes (C) compared with STRO-1+/GPA- 
osteoprogenitors (D). Intracellular localization of the particles was confirmed for the CD14+ monocytic cells (E left) as well as the 
STRO-1+/GPA- skeletal stem cell containing fraction (E right) using imaging flow cytometry. 
BF: Brightfield; BM: Bone marrow; DOPC: 1,2-dioleoyl-sn-glycero-3-phosphocholine; GPA: Glycophorin A; STRO-1: Stromal cell surface 
marker-1.
future science group
PEGylated liposomes associate with Wnt3A & expand putative SCs in human bone marrow populations    Research Article
tagged molecules immobilized and spatiality isolated 
on a glass coverslip (see schematic presentation in 
Figure 4D). Labeled proteins and liposomes were incu-
bated for a period of 5 min before imaging. The degree 
of colocalization of labeled Wnt3A protein with DiO-
labeled liposomes was significantly higher than in 
control-labeled BSA samples (31.15 ± 19.68% vs 6.89 
± 35.89% for BSA; p < 0.01; n = 27; Figure 4E & F) and 
was similar to the positive control, labeled streptavidin 
33.71 ± 25.28% (p = 0.6; Supplementary Figure 3D).
Together these imaging techniques demonstrate 
direct interaction of Wnt3A protein with liposomal 
carriers and that the stabilization of Wnt3A activity is 
likely to depend upon direct interaction of the protein 
with the synthetic lipid membrane.
Liposomes associate with monocyte & stromal 
cell/stem cell fractions of human bone marrow 
cell populations
Circulating or locally delivered liposomal preparations 
are likely to encounter a mixed cellular milieu with 
only a proportion of therapeutic dose available to a 
given cell population. To determine the representative 
uptake in primary cell populations likely to be present 
in vivo at bone injury sites, liposome-cell association 
was measured in freshly isolated human BMMNCs 
by flow cytometry. DOPC-PEG liposomes were either 
labeled with DiO or with streptavidin-AF647 for 
tracking the distribution of lipid molecules following 
cell association.
After exposure of human BMMNCs to dye-labeled 
liposomes for 3 h, a small proportion of the entire 
BMMNC fraction became dye-positive, indicating 
cellular liposome association (2.67 and 6.51% for 
DiO and AF647, respectively) (Figure 5A). In flow 
cytometry scatter plots of BMMNCs, cells of different 
populations/lineages (e.g., granulocytes, monocytes, 
lymphocytes) cluster based on their light-scattering 
properties (see Supplementary Figure 4A for details of 
gating of different BMMNC populations). The major-
ity of this association was with cells that clustered with 
cells with similar light scattering properties to mono-
cytes, but which also include skeletal/stromal stem/
progenitor populations. In this population 33.40% of 
cells were positive for DiO and 52.00% for AF647. In 
contrast, only 1.82% were positive for DiO and 4.56% 
positive for AF647 in the granulocyte gate, and 1.03% 
positive for DiO and 2.35% positive for AF647 in the 
lymphocyte gate (Figure 5B).
We have previously shown that the ‘monocyte’ gated 
cell population includes stem and progenitor cells, 
which are the intended cellular targets of Wnt activa-
tion in bone marrow and at injury sites [25]. To deter-
mine the relative association of liposomes with these 
different cell populations we immunostained dye-
labeled liposome-exposed cells for the cell surface anti-
gens CD14, STRO-1 and GPA. Liposomes associated 
to a higher degree with CD14+ monocytes (63.0 and 
84.5% for DiO- or AF647-labeled liposomes, respec-
tively; Figure 5C) than with STRO-1+/GPA− skeletal 
progenitors (4.5 vs 10.4% for DiO- or AF647-labeled 
liposomes, respectively; Figure 5D). In addition, we used 
Image Stream flow cytometry to determine whether 
DiO-labeled liposomes were internalized or remained 
adherent to the cell surface. In both CD14+ monocytes 
and STRO-1+/GPA- skeletal stem cells DiO was present 
as a punctate intracellular signal, indicated significant 
uptake within these cell populations (Figure 5E).
Together these data indicate that PEGylated lipo-
somes associate with human bone marrow cells, pri-
marily interacting with monocyte and stem/progenitor 
cells rather than granulocytes and lymphocytes.
The association of liposomes with bone 
marrow stromal cells is rapid & is not 
negatively affected by PEGylation
To determine whether PEGylation affected the rate of 
association of liposomes with stromal stem or prgenitor 
cells, we exposed cultured, adherent BMSCs to dye-
labeled liposomes and used FACS to quantify the time 
course of association.
Liposome association with cells was rapid, and 
within 3 h of incubation approximately 50% of cells 
stained positively (above a threshold set by the high-
est fluorescent intensity of an unstained sample; 
Supplementary Figure 4B), but became more gradual 
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Figure 6. Liposome associate rapidly with stromal cells of the bone marrow. Flow cytometry analysis of the uptake DiI-labeled 
liposomes by adherent stromal cells of the bone marrow after 1-, 3-, 6- and 24-h incubation. An increase in cell fluorescence (A) was 
measured after liposome incubation, as presented on the histograms representing cells exposed to liposomes (colored) versus 
control nonexposed cells (gray). For quantification of cells that were positive for the liposomes, all cells gated as positive showed a 
fluorescence intensity greater than that detected on 99% of the cells not incubated with the liposomes. All liposome preparations 
were taken up rapidly by cells, resulting in 20% of the cells positively stained with DiI dye within an hour of incubation (B). *p < 
0.05 for DOPC/PEG liposomes versus DMPC/PEG liposomes. The MFI of the geometric mean for DiI is higher for DOPC/PEG versus all 
other preparations (C; ****p < 0.0001). Data presented as mean ± SD, n = 3. MFI, mean fluorescence intensity. (D) Rate of activation 
of the Wnt signaling pathway in the reporter cell line was similar between all preparations. (E) Confocal micrographs representing 
intracellular localization of DiO-labeled liposomes (green) after 1, 3 and 24 h of incubation in stromal cells. Cells were costained with 
DAPI (blue), and the endosomal marker EEA1 (red) or the lysosomal marker LAMP1 (red). Magnification 63×, scale bars = 20 μm. Cell 
uptake was heterogeneous and the majority of the liposomes did not colocalize with the endocytic pathway vesicles. 
DAPI: 4’,6-diamidino-2-phenylindole; DMPC: 1,2-dimyristoyl-sn-glycero-3-phosphocholine; 
DOPC: 1,2-dioleoyl-sn-glycero-3-phosphocholine.
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at later time-points, with a maximum of approximately 
70% positively stained cells for the latest time-point 
measured, 24 h (Figure 6A & B). The difference in asso-
ciation between various liposome compositions was 
not significant after 1, 3 and 6 h of incubation, but 
association of DOPC/PEG liposomes labeled with DiI 
at 24 h measured by mean fluorescence intensity was 
significantly higher than other preparations (by a factor 
of ∼2.4; p < 0.0001). The kinetics of association also 
differed, with a value for Kd of 18.33 for DOPC lipo-
somes, compared with 3.35, 9.86 and 6.53 for DMPC, 
DMPC/PEG and DOPC, respectively (Figure 6C). We 
also found that PEGylated liposome preparations led 
to slightly decreased cell viability at 24 and 48 h in 
stromal cell populations (Supplementary Figure 5).
Despite subtle differences in the kinetics of associa-
tion, we found that the rate of activation of the Wnt 
signaling pathway in the reporter cell line was similar 
between preparations, with no delay or advance in the 
activation of signaling (Figure 6D).
We next examined the association of liposomes with 
cells by confocal microscopy and tested the hypoth-
esis that liposomes are endocytosed and partitioned 
to the endosomal/lysosomal pathway following cell 
interaction. Cultured BMSCs were exposed to DiO-
labeled liposomes for 1, 3 or 24 h, fixed, and imaged 
after staining with endosomal or lysosomal markers. 
The results showed increased intracellular localiza-
tion of DiO liposomes with longer incubation periods 
(representative images of the time points shown in 
Figure 6E). At the earlier time point, more cells pre-
sented with membrane staining, compared with later 
time points. Furthermore, there was little indication 
that liposomes colocalized with any of the stained cel-
lular compartments (endosomes or lysosomes).
These data indicate that both PEGylated and unPE-
Gylated liposomes rapidly associate with BMSCs, that 
they activate the Wnt signaling pathway to a similar 
degree and with similar kinetics to native protein, and 
that they initially partition to the membrane prior to 
uptake and intracellular partition.
PEGylated liposomes activate Wnt signaling 
& expand osteoprogenitors in human bone 
marrow
Finally, to address whether Wnt3A PEGylated lipo-
somes promote Wnt pathway activation to the same 
extent as Wnt3A alone, we measured β-catenin expres-
sion in MG63 osteoblastic cells after 1 h of incubation 
(Figure 7A). The expression of active, dephosphory-
lated β-catenin was increased to the same extent as 
after Wnt3A stimulation alone. Next, to assess whether 
Wnt3A PEGylated liposomes promote stem cell com-
mitment in mixed populations of cells, we exposed 
freshly isolated human BMMNCs cells to either 
PEGylated liposome associated or unassociated Wnt3A 
protein. Following a 24-h stimulation, the expression of 
AXIN2, a Wnt target gene, increased by a factor of 2.40 
± 0.36 (p < 0.01) in comparison to nonstimulated con-
trol, similar to that of Wnt3A alone control (Figure 7B). 
We also measured an increase (by a factor of 1.19 ± 
0.07; p < 0.05) in the frequency of STRO-1bright/GPA- 
fraction of BM cells, containing putative skeletal stem 
cells and osteoprogenitors, again similar to the effect 
exerted by Wnt3A alone (Figure 7C). We then cultured 
BMMNCs transiently stimulated with Wnt liposomes 
as adherent stromal cell cultures (BMSCs) for 14 days. 
In two out of three donors, transient Wnt stimulation 
increased ALPase activity at day 14, with no significant 
difference between the liposomal-Wnt3A versus unin-
corporated Wnt3A-treated cells (Figure 7D).
These experiments confirmed that the protein in the 
PEGylated liposomal formulation mimics the actions 
of the unincorporated protein, and suggests that 
PEGylated liposome preparations are suitable vehicles 
for delivery of active Wnt3A protein in mixed cellular 
milieu.
Discussion
Stable, circulating carriers such as liposomal or polymer 
nanoparticles have significant potential for delivery of 
hydrophobic proteins and molecules for treatment of 
bone disease and injury. Wnt-carrying liposomes have 
858 Nanomedicine (Lond.) (2017) 12(8)
Figure 7. PEGylated liposomes activate Wnt signaling and affect osteoprogenitors in human bone marrow. PEGylated Wnt3A DOPC 
liposomes caused an increase in active β-catenin expression, versus control samples containing liposomes without Wnt3A, comparable 
to that of Wnt3A lone (A). These liposomes also increased Wnt target gene expression, AXIN2 (B), in STRO-1-enriched BM cells over 
24 h, as well as increased the STRO-1bright/GPA- putative skeletal progenitor population (C). After 14 days of culture, cells transiently 
exposed to liposomal Wnt presented with increased bone marker expression, ALP (D). 
ALP: Alkaline phosphatase; BM: Bone marrow; GPA: Glycophorin A.
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been shown to have potential as local delivery agents 
for bone repair [29], but may have limited utility as 
circulating carriers due their rapid opsonization and 
clearance. By directly comparing the incorporation 
of Wnt3A protein at different stages of the fabrica-
tion of liposomes, we found that PEGylated DMPC 
and DOPC liposomes can retain high Wnt signaling 
activity, but only when the protein was added after 
extrusion. Single molecule spectroscopy techniques 
allowed us to show direct interaction between Wnt3A 
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molecules and liposomes, and active liposome prepara-
tions associated with and activated the Wnt signaling 
pathway in target cells with similar kinetics to native 
protein. These data illustrate the utility of PEGylated 
Wnt3A liposomes as circulating activators of Wnt 
 signaling.
In previous work, it was found that only DMPC 
was able to sustain Wnt3A-liposome activity, and that 
inclusion of PEGylated lipids completely abrogated 
it [30]. Other lipids, such as 1,2-dipalmitoyl-sn-glycero-
3-phosphocholine (DPPC), 1-myristoyl-2-palmitoyl-
sn-glycero-3-phosphocholine (MPPC) and 1-palmi-
toyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 
or combinations of them, with or without PEGylated 
DSPE, were unable to support Wnt activity. In contrast, 
in our experiments, we found that activity of Wnt3A in 
both unPEGylated and PEGylated DOPC liposomes 
was preserved, and that PEGylation of DMPC lipo-
somes reduced activity by only approximately 50%. 
This was dependent on the addition of Wnt post extru-
sion, and was time dependent, with increases in activ-
ity upon incubation for up to 24 h, as has been shown 
for DMPC liposomes previously [28]. There are several 
possible reasons why certain lipids may inhibit Wnt 
activity – these include low incorporation of protein 
in liposomes during fabrication; denaturation during 
the incorporation process; incorrect presentation of 
protein to recipient cells; or insufficient interaction/
binding of liposomes to target cell populations.
It is unlikely that differences in incorporation effi-
ciency are responsible for the differences we measured 
in activity – similar amounts of protein were measured 
in DMPC compared with PEGylated DMPC lipo-
somes, despite the latter being less active in cell culture 
assays than the former. This conclusion is supported by 
previous work where high incorporation of Wnt3A was 
observed in inactive MPPC, DPPC and POPC prepa-
rations [30]. In contrast, DOPC liposomes contained 
similar amounts of protein and had similar activi-
ties regardless of PEGylation. Therefore, PEGylation 
does not affect protein incorporation or activity per se, 
but instead reduces the ability of liposomes of certain 
chemistries to activate signaling. In parallel, we found 
similar cellular liposome association with cells for all 
preparations (Figure 6; except for DOPC liposomes, 
which had a significantly higher association), regard-
less of activity. For this reason, it is also unlikely that 
differences in the degree of liposome–cell interaction 
are responsible for differences in activity.
Instead, we consider it probable that subtle dif-
ferences in liposomal chemistry may modulate the 
mechanism of Wnt3A protein presentation to Frizzled 
receptors at the cell surface. Both DMPC and DOPC 
lipids are in a liquid crystalline form at body tempera-
ture (which we and other have found to be necessary 
for Wnt association with liposomes [39]), but DMPC 
and DOPC differ in their size and saturation – DMPC 
has a saturated 14 carbon acyl tail, while DOPC is lon-
ger (18 carbons) and is monounsaturated. Wnt3A is 
modified with palmitoleic acid at Ser209 and palmi-
tate at Cys77 [40] (although the relevance of the latter 
modification in vivo has recently been disputed [41]). 
It has been suggested that one or both of these modi-
fications facilitate stable anchorage of the protein in 
the synthetic lipid bilayer [30], although hydrophobic 
regions of the protein may also be responsible. Due to 
the presence of a single double bond, unsaturated phos-
pholipids such as DOPC have ‘kinked’ acyl chains, 
and do not align in the same manner as saturated 
phospholipids such as DMPC. This leads to looser 
packing of phospholipids in DOPC compared with 
DMPC liposomes, which may facilitate higher protein 
mobility, less stable protein/membrane binding and an 
improved ability for membrane-associated proteins to 
undergo conformational change [42,43]. To date, the 
only data available on the nature of the interaction 
of Wnt proteins with Frizzled receptors comes from 
Xenopus XWnt8, where the palmitoleic acid residue at 
Ser187 (equivalent to the same modification at Ser209 
on mammalian Wnt3A) is involved in the direct inter-
action with Frizzled [27]. Therefore, if the palmitoleic 
acid modification on Wnt3A is involved in liposome 
anchorage but is also necessary for Frizzled interac-
tion, there must be an active (energetically unfavor-
able) process by which the Wnt3A is reoriented at the 
cell surface to promote Frizzled engagement. Regard-
less of the putative mechanism of Wnt3A binding to 
liposomes, significant changes in protein orientation/
conformation of this nature are likely to be promoted 
by more loosely packed liposome lipids such as DOPC 
as compared with DMPC. This may be particularly 
true when PEG groups are present at the liposomal 
surface, which may inhibit close liposome–cell inter-
action. Future studies may address how phospholipid 
composition (for example, by varying the proportion 
of synthetic lipids and/or cholesterol) affects the stabil-
ity of Wnt3A protein interaction with liposomes using 
biochemical and biophysical techniques.
Using TCCD and TIRFM, we confirmed direct 
interaction of labeled Wnt3A protein with liposome 
carriers. TCCD has previously been used for investiga-
tion of protein aggregation [35,44] or for direct visual-
ization of protein interactions on cell membranes [45], 
but to our knowledge, this is for the first time it has 
been employed to study protein/liposome interactions. 
A similar technique, dual-color fluorescence-burst 
analysis (DCFBA) has been developed to measure the 
leakage of entrapped fluorescent molecules from lipo-
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somes [46], but TCCD in conditions of fast flow offers 
a number of advantages. These include a lack of reli-
ance on the relatively slow diffusion of liposomes (∼3 
μm2 s-1 compared with > 50 μm2 s-1 for proteins) which 
limits the data that can be collected in a static confocal 
spot, and no requirement for a binding partner (which 
may disrupt the membrane), instead detecting whether 
or not the species interacts with the liposomes. TCCD 
also offers a number of potential advantages for fur-
ther elucidating the nature and degree of interaction of 
labeled fluorescent proteins with liposomes. For exam-
ple, the sensitivity of TCCD allows one to determine 
not only if two fluorophores are coincident, but also 
how many are present, measurements important prior 
to use of drug-containing liposomes as pharmaceutical 
agents. Lifetime and Förster resonance energy trans-
fer measurements, in combination with steady-state 
TCCD and TIRFM measurements may be useful in 
determining the precise biophysical association of the 
protein with the liposomal membrane or with other 
carriers [47]. While anchorage of one of Wnt3A’s lipid 
adducts into a membrane is an attractive mechanism 
for its association with synthetic membranes such as 
liposomes, an alternate hypothesis is that hydrophobic 
domains in the protein may facilitate this interaction. 
Lifetime measurements of a protein-attached fluoro-
phore may help resolve this question, as fluorescence 
lifetime is very sensitive to solvent polarity and thus 
could be used to infer whether a portion of the pro-
tein is membrane embedded. Further single-molecule 
studies of such interactions will provide fundamental 
insight into the biophysical interactions involved in 
these transport mechanisms.
Wnt3A-associated PEGylated DOPC liposomes 
rapidly associated with human bone marrow mono-
nuclear cells extracted from patients following hip 
arthroplasty. As might be expected, the highest uptake 
was in the CD14+ monocyte population, which include 
macrophages at various stages of cell commitment. 
Macrophages are the principle cell type responsible for 
clearance of circulating liposomes, a process that has 
been exploited for many years to selectively deplete 
macrophages using liposome-encapsulated clodro-
nate [48]. However, there was also significant uptake by 
relatively rare STRO-1+/GPA- cells, a putative skeletal 
stem cell population that gives rise to bone tissue. We 
have previously shown that temporally controlled Wnt 
stimulation of these cells promotes an increase in the 
frequency of STRO-1+/GPA- cells in human bone mar-
row, and a subsequent increase in osteogenesis [25]. In 
similar experiments reported here, we find an effect of 
Wnt-associated liposomes not significantly different 
to native Wnt3A protein. Interestingly, the kinetics of 
activation of Wnt signaling were very similar, regardless 
of whether Wnt3A was delivered in its native form or 
incorporated in liposomes, which supports the notion 
that cell–surface association of liposome-associated 
Wnt3A is sufficient to induce activation. Despite this, 
liposomes were taken up and internalized by primary 
human cells, but we did not address whether liposome 
uptake was necessary for activation. Future studies may 
seek to address this by the use of specific inhibitors of 
endocytic pathways, with the caveat that receptor inter-
nalization is necessary for Wnt signaling (and so it may 
be difficult to separate the effects of liposome uptake vs 
receptor complex internalization).
It is worth noting that nanocarriers such as liposomes 
can be targeted to different cells or tissues by the inclu-
sion of motifs that are recognized or adhere to mark-
ers in certain tissues. This has recently been exploited 
to localize nanoparticles to sites of bone damage or 
repair [49,50]. Our experiments showing PEGylated 
Wnt3A-carrying nanoparticles are stable and induce 
activity in clinically relevant human cell isolates now 
provides the opportunity for spatiotemporal targeting 
of Wnt3A protein for anabolic therapies in medicine.
Conclusion
In summary, we have demonstrated that a number 
of ‘stealth’ liposomal formulations retain Wnt activ-
ity in vitro and may be used in the future as delivery 
agents to stromal/stem cell populations within the 
bone marrow niche. These results give further encour-
agement that a liposomal Wnt formulation could be 
used in future studies in systemic administration for 
promoting bone anabolism or for controlled delivery to 
fractures for repair in patients. This will be the focus 
of ongoing work.
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Summary points
PEGylated liposomes can be fabricated with uniform physical properties, & are stable for prolonged time 
periods
•	 PEGylated liposomes have a size distribution of approimately 100 nm and are stable for at least 21 days.
Wnt3A protein is active in ‘stealth’ liposomal preparations
•	 Activity of Wnt3A-containing liposomes is dependent on the method of addition.
•	 Incorporation with the protein prior to extrusion resulted only in active unPEGylated DMPC liposomes. In 
contrast, incubation of liposomes with Wnt3A post extrusion resulted in active DMPC, DOPC and PEGylated 
DOPC liposomes. Again, DMPC liposomes were not active.
•	 This was not due to a lack of protein incorporation, as the amount of Wnt3A protein present in the lipid 
pellets did not correlate with activity.
Wnt3A association with liposomes can be visualized at the single-molecule level
•	 Two color-coincidence detection and TIRF are techniques that allow visualization of direct interaction of 
labeled proteins with liposomes.
•	 For the first time, we show that Wnt3A directly associates with unPEGylated and PEGylated liposomes.
Liposomes associate with monocyte & stromal cell/stem cell fractions of human bone marrow cell 
populations
•	 After exposure of human bone marrow mononuclear isolates, PEGylated liposomes predominantly associate 
with CD14+ monocytes, but also with STRO-1+/GPA- skeletal stem cells.
•	 Liposomes do not associated significantly with granulocytes or lymphocytes.
The association of liposomes with bone marrow stromal cells is rapid & is not negatively affected by 
PEGylation
•	 PEGylation of DOPC liposomes does not affect the number of cells that associate with them, but increases the 
mean degree of uptake over 24 h.
PEGylated Wnt liposomes activate Wnt signaling & expand osteoprogenitors in human bone marrow
•	 Exposure of STRO-1+ bone marrow stromal cells increases nuclear localization of β-catenin and AXIN2 
expression, indicating activation of Wnt signaling.
•	 PEGylated DOPC Wnt3A liposomes expand osteoprogenitors and induce osteogenic differentiation to a similar 
degree to native protein.
Conclusion
•	 Active Wnt protein-containing PEGylated liposomes may have utility for systemic administration for bone 
repair.
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